This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

9 Aug 2011

FDA Nods for Orphan Drug Status of Merrimack MM-398

Merrimack Pharmaceuticals' pancreatic cancer drug has received orphan drug status approved by the FDA.

The US FDA has approved orphan drug status of Merrimack Pharmaceuticals' MM-398 as a treatment for pancreatic cancer.


MM-398 is a stable nanotherapeutic encapsulation of chemotherapy drug irinotecan.


The pancreatic cancer treatment has partnered with PharmaEngine for development and commercialisation in Taiwan under the designation PEP02.

Related News